Merck & Co. (MSD) trials: what clinicians said in public
HCP commentary reports on 11 clinical trials sponsored by Merck & Co. (MSD), including KEYNOTE-867, KEYNOTE-975, KEYNOTE-B49 and TroFuse-005. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 118 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Merck Sharp & Dohme LLC; Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| HERTHENA-Breast04 NCT07060807 · Merck Sharp & Dohme LLC | hormone receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer | Phase 3 | 27 | 5 | Focused | Nov 19, 2026 | Preview |
| OMAHA-003 NCT06136624 · Merck Sharp & Dohme LLC | mCRPC after NHA and taxane-based chemotherapy | Phase 3 | 47 | 8 | Focused | Nov 15, 2026 | Preview |
| KEYVIBE-008 NCT05224141 · Merck Sharp & Dohme LLC | first-line extensive-stage small cell lung cancer | Phase 3 | 83 | 17 | Focused | Nov 15, 2026 | Preview |
| OMAHA-004 NCT06136650 · Merck Sharp & Dohme LLC | metastatic castration-resistant prostate cancer post one NHA | Phase 3 | 72 | 7 | Focused | Nov 15, 2026 | Preview |
| KEYNOTE-975 NCT04210115 · Merck Sharp & Dohme LLC | esophageal or gastroesophageal junction carcinoma | Phase 3 | 181 | 29 | Standard | Nov 14, 2026 | Preview |
| KEYNOTE-B49 NCT04895358 · Merck Sharp & Dohme LLC | HR+/HER2- locally recurrent inoperable or metastatic breast cancer | Phase 3 | 150 | 58 | Focused | Nov 13, 2026 | Preview |
| TroFuse-005 NCT06132958 · Merck Sharp & Dohme LLC | endometrial cancer after platinum-based chemotherapy and immunotherapy | Phase 3 | 284 | 74 | Standard | Nov 13, 2026 | Preview |
| KANDLELIT-001 NCT05067283 · Merck Sharp & Dohme LLC | KRAS G12C-mutant advanced solid tumors | Phase 1 | 52 | 18 | Focused | Oct 31, 2026 | Preview |
| KEYNOTE-867 NCT03924869 · Merck Sharp & Dohme LLC | unresected stage I/II non-small cell lung cancer | Phase 3 | 258 | 55 | Standard | Oct 31, 2026 | Preview |
| INTerpath-009 NCT06623422 · Merck Sharp & Dohme LLC | resectable stage II–IIIB (N2) NSCLC not achieving pCR | Phase 3 | 82 | 18 | Focused | Oct 31, 2026 | Preview |
| INTerpath-002 NCT06077760 · Merck Sharp & Dohme LLC | resected stage II–IIIB (N2) non-small cell lung cancer | Phase 3 | 36 | 19 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| KEYNOTE-905 NCT03924895 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-B15 NCT04700124 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-811 NCT03615326 · Merck Sharp & Dohme LLC DeepView → | first-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-177 NCT02563002 · Merck Sharp & Dohme LLC DeepView → | first-line MSI-H or dMMR metastatic colorectal cancer | Phase 3 | Deep | View | |||
| KEYNOTE-024 NCT02142738 · Merck Sharp & Dohme LLC DeepView → | first-line PD-L1-high metastatic non-small-cell lung cancer | Phase 3 | Deep | View | |||
| KEYNOTE-671 NCT03425643 · Merck Sharp & Dohme LLC DeepView → | resectable stage II–IIIB non-small cell lung cancer | Phase 3 | Deep | View | |||
| LITESPARK-005 NCT04195750 · Merck Sharp & Dohme LLC DeepView → | Not given | Phase 3 | Deep | View | |||
| KEYNOTE-355 NCT02819518 · Merck Sharp & Dohme LLC DeepView → | previously untreated inoperable or metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| LITESPARK-022 NCT05239728 · Merck Sharp & Dohme LLC DeepView → | adjuvant clear cell renal cell carcinoma post nephrectomy | Phase 3 | Deep | View | |||
| KEYNOTE-522 NCT03036488 · Merck Sharp & Dohme LLC DeepView → | high-risk early-stage triple-negative breast cancer | Phase 3 | Deep | View | |||
| KEYNOTE-091 NCT02504372 · Merck Sharp & Dohme LLC DeepView → | resected stage IB-IIIA non-small-cell lung cancer | Phase 3 | Deep | View | |||
| KEYNOTE-756 NCT03725059 · Merck Sharp & Dohme LLC DeepView → | high-risk early-stage ER+/HER2- breast cancer | Phase 3 | Deep | View | |||
| KEYNOTE-866 NCT03924856 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-158 NCT02628067 · Merck Sharp & Dohme LLC DeepView → | advanced solid tumors | Phase 2 | Deep | View | |||
| LEAP-012 NCT04246177 · Merck Sharp & Dohme LLC DeepView → | incurable non-metastatic hepatocellular carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-042 NCT02220894 · Merck Sharp & Dohme LLC DeepView → | first-line PD-L1-positive advanced or metastatic non-small-cell lung cancer | Phase 3 | Deep | View | |||
| KEYNOTE-585 NCT03221426 · Merck Sharp & Dohme LLC DeepView → | locally advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-966 NCT04003636 · Merck Sharp & Dohme LLC DeepView → | first-line advanced biliary tract cancer | Phase 3 | Deep | View | |||
| KEYNOTE-057 NCT02625961 · Merck Sharp & Dohme LLC DeepView → | BCG-unresponsive high-risk non-muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| KEYNOTE-689 NCT03765918 · Merck Sharp & Dohme LLC DeepView → | resectable locally advanced HNSCC | Phase 3 | Deep | View | |||
| INTerpath-001 NCT05933577 · Merck Sharp & Dohme LLC DeepView → | high-risk stage II-IV melanoma | Phase 3 | Deep | View | |||
| LITESPARK-012 NCT04736706 · Merck Sharp & Dohme LLC DeepView → | first-line advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-A18 NCT04221945 · Merck Sharp & Dohme LLC DeepView → | high-risk locally advanced cervical cancer | Phase 3 | Deep | View | |||
| KEYNOTE-426 NCT02853331 · Merck Sharp & Dohme LLC DeepView → | first-line advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-789 NCT03515837 · Merck Sharp & Dohme LLC DeepView → | TKI-resistant EGFR-mutated metastatic nonsquamous NSCLC | Phase 3 | Deep | View | |||
| KEYNOTE-859 NCT03675737 · Merck Sharp & Dohme LLC DeepView → | HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-B96 NCT05116189 · Merck Sharp & Dohme LLC DeepView → | platinum-resistant recurrent ovarian cancer | Phase 3 | Deep | View | |||
| KEYNOTE-C93 NCT05173987 · Merck Sharp & Dohme LLC DeepView → | first-line dMMR advanced or recurrent endometrial carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-826 NCT03635567 · Merck Sharp & Dohme LLC DeepView → | first-line persistent, recurrent, or metastatic cervical cancer | Phase 3 | Deep | View | |||
| KEYNOTE-590 NCT03189719 · Merck Sharp & Dohme LLC DeepView → | first-line advanced or metastatic esophageal cancer | Phase 3 | Deep | View | |||
| KEYNOTE-001 NCT01295827 · Merck Sharp & Dohme LLC DeepView → | locally advanced or metastatic solid tumors | Phase 1 | Deep | View | |||
| LEAP-002 NCT03713593 · Merck Sharp & Dohme LLC DeepView → | first-line advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-048 NCT02358031 · Merck Sharp & Dohme LLC DeepView → | first-line recurrent/metastatic head and neck squamous cell carcinoma | Phase 3 | Deep | View | |||
| LITESPARK-011 NCT04586231 · Merck Sharp & Dohme LLC DeepView → | advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy | Phase 3 | Deep | View | |||
| KEYNOTE-045 NCT02256436 · Merck Sharp & Dohme LLC DeepView → | previously treated advanced urothelial cancer | Phase 3 | Deep | View | |||
| KEYNOTE-052 NCT02335424 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| KEYNOTE-062 NCT02494583 · Merck Sharp & Dohme LLC DeepView → | first-line advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-604 NCT03066778 · Merck Sharp & Dohme LLC DeepView → | first-line extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| EVOKE-03 NCT05609968 · Merck Sharp & Dohme LLC DeepView → | first-line PD-L1 TPS ≥50% metastatic non-small-cell lung cancer | Phase 3 | Deep | View | |||
| KEYNOTE-054 NCT02362594 · Merck Sharp & Dohme LLC DeepView → | resected high-risk stage III melanoma | Phase 3 | Deep | View | |||
| KEYNOTE-412 NCT03040999 · Merck Sharp & Dohme LLC DeepView → | locally advanced head and neck squamous cell carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-676 NCT03711032 · Merck Sharp & Dohme LLC DeepView → | high-risk non-muscle invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-564 NCT03142334 · Merck Sharp & Dohme LLC DeepView → | clear cell renal cell carcinoma post-nephrectomy | Phase 3 | Deep | View | |||
| LITESPARK-004 NCT03401788 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) DeepView → | von Hippel-Lindau disease-associated renal cell carcinoma | Phase 2 | Deep | View | |||
| KEYNOTE-630 NCT03833167 · Merck Sharp & Dohme LLC DeepView → | high-risk locally advanced cutaneous squamous cell carcinoma | Phase 3 | Deep | View | |||
| LITESPARK-013 NCT04489771 · Merck Sharp & Dohme LLC DeepView → | advanced clear cell renal cell carcinoma | Phase 2 | Deep | View | |||
| KEYNOTE-170 NCT02576990 · Merck Sharp & Dohme LLC DeepView → | relapsed or refractory primary mediastinal large B-cell lymphoma | Phase 2 | Deep | View | |||
| KEYNOTE-010 NCT01905657 · Merck Sharp & Dohme LLC DeepView → | previously treated, PD-L1-positive, advanced non-small-cell lung cancer | Phase 2/Phase 3 | Deep | View | |||
| KEYNOTE-937 NCT03867084 · Merck Sharp & Dohme LLC DeepView → | hepatocellular carcinoma after surgical resection or local ablation | Phase 3 | Deep | View | |||
| INTerpath-004 NCT06307431 · Merck Sharp & Dohme LLC DeepView → | adjuvant treatment of renal cell carcinoma | Phase 2 | Deep | View | |||
| KEYNOTE-992 NCT04241185 · Merck Sharp & Dohme LLC DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-799 NCT03631784 · Merck Sharp & Dohme LLC DeepView → | unresectable stage III non-small cell lung cancer | Phase 2 | Deep | View | |||
| KEYNOTE-B21 NCT04634877 · Merck Sharp & Dohme LLC DeepView → | newly diagnosed high-risk endometrial cancer | Phase 3 | Deep | View | |||
| KEYNOTE-240 NCT02702401 · Merck Sharp & Dohme LLC DeepView → | previously systemically treated advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-598 NCT03302234 · Merck Sharp & Dohme LLC DeepView → | untreated metastatic NSCLC with PD-L1 TPS ≥50% | Phase 3 | Deep | View | |||
| INTerpath-005 NCT06305767 · Merck Sharp & Dohme LLC DeepView → | muscle-invasive urothelial carcinoma | Phase 1/Phase 2 | Deep | View | |||
| KEYNOTE-061 NCT02370498 · Merck Sharp & Dohme LLC DeepView → | previously treated advanced gastric/gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-921 NCT03834506 · Merck Sharp & Dohme LLC DeepView → | chemotherapy-naïve metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| LEAP-011 NCT03898180 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| LEAP-015 NCT04662710 · Merck Sharp & Dohme LLC DeepView → | first-line advanced/metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-365 NCT02861573 · Merck Sharp & Dohme LLC DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| KEYNOTE-224 NCT02702414 · Merck Sharp & Dohme LLC DeepView → | advanced hepatocellular carcinoma | Phase 2 | Deep | View | |||
| KEYLYNK-001 NCT03740165 · Merck Sharp & Dohme LLC DeepView → | first-line BRCA non-mutated advanced epithelial ovarian cancer | Phase 3 | Deep | View | |||
| KEYLYNK-010 NCT03834519 · Merck Sharp & Dohme LLC DeepView → | previously treated biomarker-unselected metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| LITESPARK-024 NCT05468697 · Merck Sharp & Dohme LLC StandardView → | advanced renal cell carcinoma | Phase 1/Phase 2 | Standard | View | |||
| KEYNOTE-021 NCT02039674 · Merck Sharp & Dohme LLC StandardView → | locally advanced or metastatic non-small cell lung carcinoma | Phase 1/Phase 2 | Standard | View | |||
| KEYNOTE-012 NCT01848834 · Merck Sharp & Dohme LLC StandardView → | advanced solid tumors | Phase 1 | Standard | View | |||
| KEYNOTE-013 NCT01953692 · Merck Sharp & Dohme LLC StandardView → | hematologic malignancies | Phase 1 | Standard | View | |||
| TroFuse-010 NCT06312176 · Merck Sharp & Dohme LLC StandardView → | HR+/HER2- unresectable locally advanced or metastatic breast cancer | Phase 3 | Standard | View | |||
| KEYNOTE-059 NCT02335411 · Merck Sharp & Dohme LLC StandardView → | advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Standard | View | |||
| KEYLYNK-012 NCT04380636 · Merck Sharp & Dohme LLC StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| LEAP-005 NCT03797326 · Merck Sharp & Dohme LLC StandardView → | previously treated advanced solid tumors | Phase 2 | Standard | View | |||
| KEYMAKER-U04 NCT05845814 · Merck Sharp & Dohme LLC StandardView → | first-line metastatic urothelial carcinoma | Phase 1/Phase 2 | Standard | View | |||
| KEYNOTE-087 NCT02453594 · Merck Sharp & Dohme LLC StandardView → | relapsed or refractory classical Hodgkin lymphoma | Phase 2 | Standard | View | |||
| KEYNOTE-199 NCT02787005 · Merck Sharp & Dohme LLC StandardView → | metastatic castration-resistant prostate cancer | Phase 2 | Standard | View | |||
| KEYNOTE-629 NCT03284424 · Merck Sharp & Dohme LLC StandardView → | locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma | Phase 2 | Standard | View | |||
| LEAP-006 NCT03829319 · Merck Sharp & Dohme LLC StandardView → | first-line metastatic nonsquamous non-small cell lung cancer | Phase 3 | Standard | View | |||
| KEYNOTE-185 NCT02579863 · Merck Sharp & Dohme LLC StandardView → | newly diagnosed treatment-naive multiple myeloma | Phase 3 | Standard | View | |||
| KEYVIBE-006 NCT05298423 · Merck Sharp & Dohme LLC StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| MK-3475A-D77 NCT05722015 · Merck Sharp & Dohme LLC StandardView → | first-line metastatic non-small cell lung cancer | Phase 3 | Standard | View | |||
| TroFuse-033 NCT06952504 · Merck Sharp & Dohme LLC StandardView → | mismatch repair-proficient endometrial cancer, first-line maintenance | Phase 3 | Standard | View | |||
| IDeate-Prostate01 NCT06925737 · Merck Sharp & Dohme LLC StandardView → | metastatic castration-resistant prostate cancer | Phase 3 | Standard | View | |||
| KEYNOTE-189 NCT02578680 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| LITESPARK-003 NCT03634540 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) FocusedView → | advanced clear cell renal cell carcinoma | Phase 2 | Focused | View | |||
| NCT04471727 NCT04471727 · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| KEYNOTE-407 NCT02775435 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| LEAP-007 NCT03829332 · Merck Sharp & Dohme LLC FocusedView → | PD-L1-positive treatment-naïve metastatic NSCLC | Phase 3 | Focused | View | |||
| KEYFORM-008 NCT05508867 · Merck Sharp & Dohme LLC FocusedView → | PD-(L)1-refractory relapsed or refractory classical Hodgkin lymphoma | Phase 2 | Focused | View | |||
| TroFuse-007 NCT06170788 · Merck Sharp & Dohme LLC FocusedView → | first-line metastatic NSCLC with PD-L1 TPS ≥50% | Phase 3 | Focused | View | |||
| TroFuse-032 NCT06966700 · Merck Sharp & Dohme LLC FocusedView → | early-stage triple-negative or HR-low+/HER2− breast cancer | Phase 3 | Focused | View | |||
| KEYNOTE-361 NCT02853305 · Merck Sharp & Dohme LLC FocusedView → | first-line advanced or metastatic urothelial carcinoma | Phase 3 | Focused | View | |||
| LITESPARK-001 NCT02974738 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||
| KANDLELIT-004 NCT06345729 · Merck Sharp & Dohme LLC FocusedView → | KRAS G12C-mutant NSCLC with PD-L1 TPS ≥50% | Phase 3 | Focused | View | |||
| KEYMAKER-U03 NCT04626518 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| INTerpath-007 NCT06295809 · Merck Sharp & Dohme LLC FocusedView → | resectable locally advanced cutaneous squamous cell carcinoma | Phase 2/Phase 3 | Focused | View | |||
| TroFuse-031 NCT07419295 · Merck Sharp & Dohme LLC FocusedView → | pretreated locally advanced/metastatic urothelial carcinoma | Phase 3 | Focused | View | |||
| KEYNOTE-122 NCT02611960 · Merck Sharp & Dohme LLC FocusedView → | platinum pre-treated recurrent or metastatic nasopharyngeal cancer | Phase 3 | Focused | View | |||
| KEYNOTE-427 NCT02853344 · Merck Sharp & Dohme LLC FocusedView → | locally advanced/metastatic renal cell carcinoma | Phase 2 | Focused | View | |||
| TroFuse-011 NCT06841354 · Merck Sharp & Dohme LLC FocusedView → | previously untreated PD-L1 CPS<10 advanced triple-negative breast cancer | Phase 3 | Focused | View | |||
| KEYMAKER-U03 NCT04626479 · Merck Sharp & Dohme LLC FocusedView → | first-line advanced clear-cell renal cell carcinoma | Phase 1/Phase 2 | Focused | View | |||
| KEYNOTE-B61 NCT04704219 · Merck Sharp & Dohme LLC FocusedView → | first-line advanced non-clear-cell renal cell carcinoma | Phase 2 | Focused | View | |||
| TroFuse-019 NCT06312137 · Merck Sharp & Dohme LLC FocusedView → | resectable stage II–IIIB (N2) NSCLC not achieving pCR | Phase 3 | Focused | View | |||
| KANDLELIT-007 NCT07190248 · Merck Sharp & Dohme LLC FocusedView → | first-line KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC | Phase 3 | Focused | View | |||
| INTerpath-13 NCT07221474 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 2 | Focused | View | |||
| MK-1026-001 NCT03162536 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) FocusedView → | relapsed or refractory hematologic malignancies | Phase 1/Phase 2 | Focused | View | |||
| KEYNOTE-716 NCT03553836 · Merck Sharp & Dohme LLC FocusedView → | resected stage IIB or IIC melanoma | Phase 3 | Focused | View | |||
| KEYNOTE-641 NCT03834493 · Merck Sharp & Dohme LLC FocusedView → | metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| KEYNOTE-407 NCT03875092 · Merck Sharp & Dohme LLC FocusedView → | first-line metastatic squamous non-small cell lung cancer | Phase 3 | Focused | View | |||
| KEYNOTE-189 NCT03950674 · Merck Sharp & Dohme LLC FocusedView → | first-line metastatic nonsquamous non-small cell lung cancer | Phase 3 | Focused | View | |||
| LEAP-008 NCT03976375 · Merck Sharp & Dohme LLC FocusedView → | metastatic NSCLC after platinum chemotherapy and immunotherapy | Phase 3 | Focused | View | |||
| KEYNOTE-991 NCT04191096 · Merck Sharp & Dohme LLC FocusedView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Focused | View | |||
| NCT04254978 NCT04254978 · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT04924075 NCT04924075 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 2 | Focused | View | |||
| KEYNOTE-C11 NCT05008224 · Merck Sharp & Dohme LLC FocusedView → | newly diagnosed classical Hodgkin lymphoma | Phase 2 | Focused | View | |||
| NCT06074588 NCT06074588 · Merck Sharp & Dohme LLC FocusedView → | previously treated advanced nonsquamous NSCLC with genomic alterations | Phase 3 | Focused | View | |||
| NCT06305754 NCT06305754 · Merck Sharp & Dohme LLC FocusedView → | EGFR-mutated advanced nonsquamous non-small cell lung cancer | Phase 3 | Focused | View | |||
| NCT06393374 NCT06393374 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| INTerpath-014 NCT07513376 · Merck Sharp & Dohme LLC FocusedView → | resected high-risk stage I non-small cell lung cancer | Phase 3 | Focused | View | |||